Beta
ManageSearchChatDiscover
174137

ROSIGLITAZONE SHOWS SEQUENCE-SPECIFIC SYNERGY WITH CHEMOTHERAPEUTIC DRUGS IN INHIBITION OF MCF-7 BREAST CANCER CELL LINE

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Preclinical studies have shown that peroxisome proliferator-activated receptor γ (PPARγ) ligands such as thiazolidinediones (TZDs) can exert antitumor effects against breast cancer and a variety of other cancers. In this study, we investigated the potential of repurposing a PPARγ ligand, rosiglitazone (RGZ), in combination with either of three chemotherapeutic agents, doxorubicin (Dox) or cisplatin (Cis) or 5-fluorouracil (5-FU), for the in-vitro treatment of breast cancer cell line, MCF-7. RGZ augmented the growth inhibition effect of Cis and 5-FU on MCF-7 cells. The synergy was observed only when chemotherapy preceded RGZ and not vice versa, demonstrating a sequence-specific effect. We also observed that the first administered drug gave its cell cycle pattern and apoptosis/necrosis pattern to the subsequently applied drug. Besides, no adipose differentiation in the form of lipid droplet accumulation was induced in treated cells regardless of the used drugs and their sequence of application. Together, our data show a synergistic effect of administering RGZ after Cis or 5-FU and suggests an inhibitory role of RGZ on the chemo-resistant MCF-7 side-populations.

DOI

10.21608/bfsa.2021.174137

Authors

First Name

Sally

Last Name

Al-Moualem

MiddleName

-

Affiliation

Program of Molecular Biology and Biotechnology, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria

Email

-

City

-

Orcid

-

First Name

Fawza

Last Name

Monem

MiddleName

-

Affiliation

Program of Molecular Biology and Biotechnology, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria & Department of Clinical Laboratories, Al-Assad Hospital, Damascus, Syria

Email

fawzamonem@hotmail.com

City

-

Orcid

0000-0002-1695-0524

Volume

44

Article Issue

1

Related Issue

25283

Issue Date

2021-06-01

Receive Date

2020-10-25

Publish Date

2021-06-01

Page Start

119

Page End

130

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 44_Issue 1_Pages 119-130.pdf

PDF . 1.9MB

Link

https://bpsa.journals.ekb.eg/article_174137.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=174137

Order

12

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

ROSIGLITAZONE SHOWS SEQUENCE-SPECIFIC SYNERGY WITH CHEMOTHERAPEUTIC DRUGS IN INHIBITION OF MCF-7 BREAST CANCER CELL LINE

Details

Type

Article

Created At

22 Jan 2023